Similarly, the 2022 European Leukemia Net (ELN) recommendations incorporated mutations in BCOR, EZH2, SF3B1, SRSF2, STAG2, U2AF1, and ZRSR2 into the adverse risk category of AML on top of their 2017’s recommendations to define cases with an MDS-like signature [64,65]. The gene discussed is U2AF1; the disease is acute myeloid leukemia.